Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name U2AF1 S34F
Gene Variant Detail

U2AF1 S34F (gain of function)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
U2AF1 S34F acute myeloid leukemia sensitive E7107 Preclinical - Patient cell culture Actionable In a preclinical study, patient-derived acute myeloid leukemia cells harboring U2AF1 S34F were sensitive to E7107 in cell culture (PMID: 28067246). 28067246
U2AF1 S34F lung cancer sensitive H3B-8800 Preclinical - Cell line xenograft Actionable In a preclinical study, H3B-8800 preferentially inhibited growth of lung cancer cells harboring U2AF1 S34F compared to U2AF1 wild-type cells in culture and in cell line xenograft models (Cancer Res 2017;77(13 Suppl):Abstract nr 1185). detail...
U2AF1 S34F acute myeloid leukemia sensitive Sudemycin D6 Preclinical Actionable In a preclinical study, Sudemycin D6 treatment induced cell cycle arrest and growth inhibition in acute myeloid leukemia cell lines expressing U2AF1 S34F in culture, and inhibited progenitor cells expansion in transgenic mouse models (PMID: 28067246). 28067246
U2AF1 S34F acute myeloid leukemia sensitive Indisulam Preclinical - Cell culture Actionable In a preclinical study, an acute myeloid leukemia cell line engineered to express U2AF1 S34F from the endogenous locus demonstrated increased sensitivity to Indisulam (E7070) induced growth inhibition compared to parental cells in culture (PMID: 30799057). 30799057
U2AF1 S34F acute myeloid leukemia sensitive E7820 Preclinical - Cell culture Actionable In a preclinical study, an acute myeloid leukemia cell line engineered to express U2AF1 S34F from the endogenous locus demonstrated increased sensitivity to E7820 induced growth inhibition compared to parental cells in culture (PMID: 30799057). 30799057
Clinical Trial Phase Therapies Title Recruitment Status